Claypoole Robert E 4

What Happened

• Robert E. Claypoole, President, CEO and Director of Bioventus (BVS), converted/exercised 33,500 derivative awards into Class A common shares on 2026-03-13. To satisfy tax withholding obligations, 14,553 of those shares were surrendered at an effective price of $8.62, yielding $125,447. The filing also records multiple prior and contemporaneous awards (RSUs/options) granted in 2025 and 2026.

Key Details

• Primary transaction dates: 2026-03-13 (conversion/exercise and tax withholding) and prior grant dates 2025-03-14 and 2026-03-13.
• Conversion/exercise: 33,500 derivative shares converted into common stock on 2026-03-13 (reported $0.00 per share, consistent with RSU conversion).
• Tax withholding (code F): 14,553 shares surrendered at $8.62 per share to satisfy withholding = $125,447.
• Awards reported (grants/derivatives): 134,000 and 153,000 (granted 2025-03-14), and 278,000 and 309,000 (granted 2026-03-13) — aggregate 874,000 RSUs/options shown in the filing.
• Footnotes: F1—each RSU equals a contingent right to one share; F2/F3—RSUs/options vest in four equal annual installments beginning March 15, 2025 (for the 2025 grants) and March 15, 2026 (for the 2026 grants), subject to continued service.
• Shares owned after the transactions are not specified in the provided data.
• Filing date: 2026-03-17. The filing lists transactions on 2025-03-14 and 2026-03-13; no late-filing flag was provided in the materials you supplied.

Context

• This appears to be a routine compensation/vesting event (conversion of RSUs/options) rather than an open-market buy or sell. The surrender of shares was for tax withholding (common in net settlement of RSUs) rather than a market sale for investment purposes.
• For retail investors: such conversion/withholding events reflect compensation vesting and do not necessarily indicate the insider is bullish or bearish on the stock.